"Accelerating Entry into the Central and South American Market"

Inibio announced on March 23 that it recently held a launch symposium for its botulinum toxin product, "Inibo," in Peru.

Inibio Holds Symposium for Botulinum Toxin "Inibo" in Peru View original image

The event, held in Lima, Peru, was attended by over 110 professionals and stakeholders in the field of aesthetic medicine. The symposium was organized to introduce the characteristics and clinical applications of Inibo, featuring an academic program focused on the clear origin of the strain, as well as safety and efficacy based on ultra-high purity.


This symposium marks Inibio's first step in targeting the Central and South American market since it obtained a new product approval from the Peruvian Directorate General of Medicines, Supplies and Drugs (DIGEMID) in July last year. In particular, Peru is one of the fastest-growing countries in the aesthetic medicine market in Central and South America, and the company expects that the symposium will further strengthen the Inibo brand's position in the global toxin market.



A representative from Inibio stated, "This event was a significant opportunity to introduce Inibo to the Central and South American market for the first time," adding, "We will solidify the foundation for market expansion by strengthening our academic network with local medical professionals."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing